Scinai Immunotherapeutics... (SCNI)
3.44
0.03 (0.88%)
At close: Jan 14, 2025, 1:45 PM
3.40
-1.20%
After-hours Jan 14, 2025, 04:20 PM EST
undefined% (undefined)
| Bid | 3.4 |
| Market Cap | 2.94M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 2.4 |
| PE Ratio (ttm) | 1.43 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 3.48 |
| Volume | 2,964 |
| Avg. Volume (20D) | 11,624 |
| Open | 3.52 |
| Previous Close | 3.41 |
| Day's Range | 3.42 - 3.52 |
| 52-Week Range | 2.23 - 8.92 |
| Beta | undefined |
About SCNI
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and devel...
Industry Biotechnology
Sector Healthcare
IPO Date May 11, 2015
Employees 31
Stock Exchange NASDAQ
Ticker Symbol SCNI
Website https://www.scinai.com
1 month ago ·
Source
+0.88%
Scinai Immunotherapeutics share are trading higher...
Unlock content with
Pro Subscription
1 month ago ·
Source
+17.22%
Scinai Immunotherapeutics shares are trading higher after the company reported a year-over-year increase in Q3 EPS results.
4 months ago · seekingalpha.com
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call TranscriptScinai Immunotherapeutics Ltd. (NASDAQ:SCNI ) Q2 2024 Results Conference Call August 20, 2024 11:00 AM ET Company Participants Liat Halpert - Head of Business Development Amir Reichman - CEO Liat Halp...
